Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

2-Hydroxybenzylamine (2-HOBA) to Reduce HDL Modification and Improve HDL Function in Familial Hypercholesterolemia (FH)

NCT04941599 is registered in ClinicalTrials.gov with Vanderbilt University Medical Center as lead sponsor.

NCT NCT04941599
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT04941599 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
2-Hydroxybenzylamine (2-HOBA) to Reduce HDL Modification and Improve HDL Function in Familial Hypercholesterolemia (FH)
Lead sponsor
Vanderbilt University Medical Center
Phase
Phase 2
Overall status
Recruiting
Start date
February 14, 2024
Completion date
December 31, 2027
Enrollment
72 (estimated)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

familial hypercholesterolemia